Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 14, 2021

Sorrento secures UK MHRA approval for intranasal Covid-19 drug trial

The efficacy trial will complement a Phase II trial in the US as well as a trial set to begin in Mexico.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has permitted Sorrento Therapeutics to commence a Phase II efficacy trial of its product candidate, COVI-DROPS, to treat Covid-19 in the outpatient setting.

Administered intranasally, COVI-DROPS contain a neutralising antibody that potentially works against the original SARS-CoV-2 virus and the UK/Alpha and India/Delta variants.

Sorrento submitted the Phase II trial application through a rolling submission approach and received MHRA clearance in under a month from its first filing with the regulatory agency.

The submission was backed by the safety data from a US study in healthy subjects, where the product candidate demonstrated a safety profile comparable to placebo with doses of up to 60mg.

Furthermore, no serious adverse effects or dose-limiting toxicities were noted in the study, with all adverse effects being mild.

The company noted that the maximum tolerated dose was not reached.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The large, randomised, double-blind, Phase II efficacy trial will enrol 350 asymptomatic or mildly symptomatic outpatients with Covid-19.

Participants will be categorised in a 2:2:1 ratio to receive either a 10mg or 20mg dose of the product or placebo.

Sorrento noted that the latest trial will support a Phase II study in the US and a separate trial in Mexico.

The Phase II efficacy trial results in the UK will be merged with the data from the US and Mexico studies.

If COVI-DROPS is found to be safe and effective against SARS-CoV-2, Sorrento plans to seek emergency use authorisation in the US, India, UK, Mexico, EU, and other regions.

In a separate development, the US Food and Drug Administration (FDA) has accepted the investigational new drug (IND) application of Vicore Pharma’s lead candidate, C21, for treating Covid-19.

The active IND aids in commencing Phase III ATTRACT-3 trial of the angiotensin II type 2 receptor (AT2R) agonist at various centres in the US.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy